– USA, NJ – Valeritas Holdings, Inc. (NASDAQ:VLRX) announced today the election of Katherine D. Crothall, PhD, to the Company’s Board of Directors, effective October 10, 2016. Dr. Crothall will serve as an independent director, bringing the total number of independent directors to four. In conjunction with the appointment of Dr. Crothall, Cameron Hui, who represents CRG, will step down from the Board of Directors as of October 10, resulting in a Board with a majority of independent directors.
John Timberlake, President and Chief Executive Officer of Valeritas, said, “We are thrilled to welcome Kathy to the Valeritas Board of Directors. Kathy brings a wealth of diabetes device experience from her time at Animas, which she founded and led through a successful commercial ramp-up until it was ultimately acquired by J&J. She knows what it takes to drive the adoption of an innovative technology in the diabetes marketplace and brings a proven track record of building and growing several successful medical device companies. We believe she will make significant contributions to Valeritas and look forward to working with her.”
Dr. Crothall commented, “Valeritas has a unique opportunity to significantly improve the lives of people living with Type 2 diabetes. V-Go has all of the attributes of a product poised to gain broad adoption, including outstanding clinical data, convenience, ease-of-use, discreet dosing and cost-effectiveness. I look forward to being a part of providing people with Type 2 diabetes such an innovative solution to improved insulin management as Valeritas executes on its capital-efficient commercial strategy.”
Dr. Crothall currently serves as President, CEO, and Chairman of the Board of Aspire Bariatrics, a company committed to providing safe and effective treatments for obesity to patients worldwide. Prior to Aspire, Dr. Crothall was a Principal at Liberty Venture Partners, a venture capital firm located in Philadelphia, from 2006 until November 2010. Prior to Liberty, Dr. Crothall was Founder, President, and CEO of Animas Corporation, a leading manufacturer of insulin infusion pumps located in West Chester, PA, from its inception to its acquisition by Johnson & Johnson (J&J) Corporation in February 2006. Prior to Animas, Dr. Crothall was also the Founder, President, and CEO of two other medical device companies; Luxar Corporation (Seattle, WA) was founded in 1988 and was sold to ESC Medical, and Laakmann Electro-Optics, founded in 1978, was sold to Johnson & Johnson in 1981. Dr. Crothall continued running Laakmann Electro-Optics for five years post-acquisition.
Dr. Crothall received her BS from University of Pennsylvania and her PhD from University of Southern California, both in Electrical Engineering. She holds over 20 patents and is the recipient of several awards including the Ernst & Young Entrepreneur of the Year Award in 2003 and the Greater Philadelphia Raymond Rafferty Entrepreneurial Excellence Award in 2004. Dr. Crothall is a director of Adhezion BioMedical and Xanitos, Inc. She also sits on the Board of Overseers of the School of Engineering and Applied Sciences at the University of Pennsylvania.
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company focused on developing innovative technologies to improve the health and quality of life of people with Type 2 diabetes. Valeritas’s flagship product, V-Go Disposable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery solution for patients with Type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in a state-of-the-art facility in Shrewsbury, Massachusetts.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
